BioGaia moves into the black

By staff reporter

- Last updated on GMT

Related tags Lactobacillus Reuteri Biogaia

BioGaia has reported significant gains in full year 2006 that tip
it into profit, thanks largely to deals for finished probiotic
products in a widening geographical sphere.

The Swedish biotech is involved in the research and development of products using the lactic acid bacterium Lactobacillus reuteri​ (Reuteri), including novel delivery systems to elongate shelf life. In its year-end results, BioGaia has reported after-tax operating profit of SEK 2.7m (c €0.29m), up from SEK –19.8m (-€2.15m) last year. Net sales for the year were up 46 per cent to SEK 86.8m (€9.4m) Although BioGaia's main sales activities relate to finished probiotic products like tablets, drops, and oral health products, it also sells license rights for the use of Reuteri cultures in a customer's own products, such as yoghurts and infant formula. On this front, the most significant news in 2006 came early on in the year, with the signing of an agreement with Novartis Consumer Health for the use of Reuteri and delivery technology in medical nutrition products. Key events in the fourth quarter included the signing of distribution and marketing agreements in Central Eastern Europe (Ewopharma), Germany (HSO Pharma), Indonesia (PT Kalbe Pharma), and "four key markets in Europe"​ (oral health products, Sunstar Suisse). BioGaia is also looking to make inroads in the Japanese – the single country with the biggest supplements market in the world. In Q3 it established a wholly-owned subsidiary in Hiroshima, which plans to launch products in the country under the BioGaia brand in 2007. BioGaia is continuing with its research programme, and its R&D spend for the year was SEK 18.8m (€2.04m). Although this was SEK 5.7m (€0.62m) less than 2005, the prior year figure included more than SEK 5m (€0.5m) in one-off expenses relating to the allergy research product aborted in December 2005. At the beginning of 2007, a clinical study in Reuteri's effects on colicky infants was published in the journal Pediatrics​, and received much media attention. BioGaia's stated objective is to "attain solid and sustainable profitability".​ It said: "In view of the company's strong portfolio of innovative products, successful clinical trials and growing distribution network covering a large share of the key markets, BioGaia's future outlook is bright."

Related news

Show more

Related products

show more

New postbiotic for gut & skin health benefits

New postbiotic for gut & skin health benefits

Content provided by Kerry ProActive Health | 14-May-2024 | Product Presentation

Plenibiotic™ (Lactobacillus casei subsp. casei 327) is a rice-derived postbiotic providing a holistic approach to digestive and skin health. It offers...

Redefine resilience with IMMUSE

Redefine resilience with IMMUSE

Content provided by Kyowa Hakko (US) | 02-May-2024 | White Paper

IMMUSETM is a universal postbiotic — the first of its kind to activate pDC cells for year-round immune support.

Related suppliers

Follow us

Products

View more

Webinars